

salbutamol's good

but
Combivent UDVs
are better

New *Combivent*



A convenient solution for greater Oompah in COPD

How to reach the parts other
methods cannot reach...

Qualitative Research in Health Care

Edited by **Michael May** and **Catherine Pope**

Find out all you need to know about qualitative
research methods in this unique introduction for
health care professionals.

Written in a user-friendly style with a minimum of
jargon, this practical book:

- Describes all the most commonly used methods
such as focus groups, interviews, and consensus
methods.
- Gives real life examples of how these methods
can be applied in health care research.
- Outlines the benefits and common pitfalls
for each approach.
- Is ideal for all clinicians, GPs, and other health
workers involved in research.

Make sure your research
giving you the complete
picture - order your copy
of *Qualitative Research*
today!

ISBN 0 7279 1013 2

110 pages

January 1996

UK £10.95

Overseas £13.00

Health professionals

£9.95; £12.00

Also available:

Systematic Reviews

Edited by **Iain Chalmers**, **Doug Altman**

A concise introduction to systematic reviews,
illustrated with real life case studies.

UK £14.95; Overseas £17.00

Health professionals £13.95; £16.00

To order by phone call our credit card hotline on
0171 383 6185/6245 (fax 0171 383 6662) with Visa,
Mastercard or Amex card details.

Alternatively write to BMJ Publishing Group,
PO Box 295, London WC1H 9TE enclosing
your cheque made payable to BMJ.

Also available from medical booksellers,
including the BMJ Bookshop at BMA House.

BMJ
Publishing
Group

Salamol Easi-Breathe™ Inhaler **Salbutamol BP Inhaler**

(Please refer to full data sheet before prescribing)

Presentation Metered-Dose Aerosol supplied in a Breath-Operated Inhaler containing 200 doses. Salamol Easi-Breathe Inhaler delivers 100mcg of Salbutamol BP per actuation.

Uses Provides automatic actuation of inhaler with inspiration. For the treatment and prophylaxis of bronchial asthma.

Dosage and Administration Use as required. **Adults** (i) Acute bronchospasm and intermittent episodes of asthma, including relief of symptoms - one or two inhalations as a single dose. (ii) Chronic maintenance or prophylactic therapy - two inhalations three or four times daily. (iii) To prevent exercise induced bronchospasm - two inhalations should be taken before exertion. **Children** (i) Acute bronchospasm and episodic asthma, including relief of symptoms, or before exercise - one inhalation. (ii) Routine maintenance or prophylactic therapy - one inhalation three or four times daily. The doses in children may be increased to two inhalations. Children should be supervised. Allow 4 hours between each dose. No more than 4 doses in any 24 hours.

Contra-indications Managing premature labour or threatened abortion. Hypersensitivity to any of the components.

Warnings Potentially serious hypokalaemia may result from beta₂-agonist therapy and may be potentiated by concomitant drugs or hypoxia - serum potassium levels should be monitored in this situation. Propranolol and other non-cardioselective beta-adrenoceptor blocking agents antagonise the effect of salbutamol.

Precautions Cautious use in patients with hyperthyroidism, who are hypersusceptible or who are suffering from diabetes mellitus, serious cardiovascular disorders or hypertension. Alternative or additional therapy including corticosteroids should be instituted promptly in asthmatic patients whose condition deteriorates despite salbutamol therapy. Adverse metabolic effects of high doses of salbutamol may be exacerbated by concomitant administration of high doses of corticosteroids.

Side Effects Potentially serious hypokalaemia (see Warnings). Salbutamol may cause fine tremor of skeletal muscle, palpitations, muscle cramps, slight tachycardia, tenseness, headaches and peripheral vasodilatation. Reports of hyperactivity in children or hypersensitivity reactions are rare.

Pregnancy/Lactation Use inhalers only if the potential benefit outweighs the risk.

Product Licence Number and Basic NHS Cost

PL 0530/0399 £6.30

Legal Category POM

Further Information is available on request from: Baker Norton, Gemini House, Flex Meadow, Harlow, Essex CM19 5TJ

Beclazone Easi-Breathe™ Inhaler

Beclomethasone Dipropionate BP Inhaler

(Please refer to full data sheet before prescribing)

Presentation Metered-Dose Aerosol supplied in a Breath-Operated Inhaler containing 200 doses. **Beclazone 50 Easi-Breathe, Beclazone 100 Easi-Breathe and Beclazone 250 Easi-Breathe Inhalers** deliver 50, 100 and 250 microgram Beclomethasone Dipropionate BP per actuation of the valve.

Uses Provides automatic actuation of inhaler with inspiration. For the management of bronchial asthma especially in patients inadequately controlled by bronchodilators and sodium cromoglycate.

Dosage and Administration Use regularly. **Adults, Beclazone 50 and 100 Easi-Breathe Inhalers;** 100 microgram three or four times daily. **Beclazone 250 Easi-Breathe Inhaler;** 500 microgram twice a day or 250 microgram four times a day.

Elderly; no dose adjustment necessary, including patients with renal or hepatic impairment. **Children, Beclazone 50 and 100 Easi-Breathe Inhalers;** 50 to 100 microgram two to four times daily. **Beclazone 250 Easi-Breathe Inhaler** is not indicated for use in children.

Contra-indications Hypersensitivity to the ingredients.

Precautions Patients should be instructed in the correct use of inhalers. May induce systemic cortico-steroid effects (with reduction in plasma cortisol levels) and adrenal suppression (above 2000 microgram daily) - monitor adrenal function and provide systemic steroids in appropriate cases of stress. Caution in patients with history of, or active pulmonary tuberculosis. Avoid sudden cessation of treatment.

Pregnancy/Lactation Use inhalers only if the potential benefit outweighs the risk.

Side Effects Paradoxical bronchospasm - discontinue use immediately and seek medical advice. Candidiasis, hoarseness or throat irritation - relieve by rinsing throat with water.

Product Licence Numbers and Basic NHS Cost

Beclazone 50 Easi-Breathe Inhaler - PL 0530/0451 £4.34

Beclazone 100 Easi-Breathe Inhaler - PL 0530/0452 £8.24

Beclazone 250 Easi-Breathe Inhaler - PL 0530/0453 £18.02

Legal Category POM

Further Information is available on request from: Baker Norton, Gemini House, Flex Meadow, Harlow, Essex CM19 5TJ

Date of Issue January 1996

Date of Preparation December 1995

BAKIER
NORTON

The freedom to prescribe

Salamol, Salamol Easi-Breathe, Beclazone, Beclazone Easi-Breathe and Baker Norton are trademarks of Norton Healthcare Limited.

BNEB0196/A4

Designed for living

...priced for everyone

The Easi-Breathe breath-operated inhalers are designed to help save lives. Perhaps it doesn't matter that many asthma patients can't use their salbutamol inhaler properly – they just take more doses until they feel an effect – but with a preventative, such as beclomethasone, the results could be serious.

Easi-Breathe inhalers offer both these therapies in breath-operated inhalers that breathe new life into asthma treatment. Literally, all you do is open...breathe...and close. There's no need to co-ordinate release, and the low inspiratory effort makes Easi-Breathe suitable for a wide range of patients.

Of course, you'd give all your asthma patients a better inhaler if cost wasn't an issue. Well, now it isn't. Easi-Breathe beclomethasone inhalers actually cost up to 22% less than ordinary press-and-breathe inhalers, and the salbutamol is also competitively priced (even before eliminating those 'extra puffs') – so there's no need for patients to use another inhaler for either of

these treatments.

Beclazone and Salamol Easi-Breathe inhalers are convenient, economical, simple and effective. They're designed for living, and priced for everyone.


Easi-Breathe

Beclazone *Easi-Breathe*

**Beclomethasone Dipropionate BP
50, 100 & 250 microgram inhalers**

Salamol *Easi-Breathe*

**Salbutamol BP
100 microgram inhaler**



ABBREVIATED PRESCRIBING INFORMATION

Presentation UNIPHYLLIN CONTINUS tablets contain Theophylline BP in a controlled release system. UNIPHYLLIN CONTINUS tablets 400 mg are white, capsule-shaped, scored tablets with the logo NAPP U400 embossed on one side and UNIPHYLLIN on the other. UNIPHYLLIN CONTINUS tablets 300 mg are white, capsule-shaped, scored tablets with U300 embossed on one side. UNIPHYLLIN CONTINUS tablets 200 mg are white, capsule-shaped, scored tablets with U200 embossed on one side. **Uses** Theophylline is a bronchodilator. In addition it affects the function of a number of cells involved in the inflammatory processes associated with asthma and chronic obstructive airways disease. Of most importance may be enhanced suppressor T-lymphocyte activity and reduction of eosinophil and neutrophil function. These actions may contribute to anti-inflammatory prophylactic activity in asthma and chronic obstructive airways disease. For the treatment and prophylaxis of bronchospasm associated with asthma, emphysema and chronic bronchitis. Also indicated in adults for the treatment of cardiac asthma and left ventricular or congestive cardiac failure. **Dosage and administration** NB Tablets should be swallowed whole and not chewed. **Adults:** The usual maintenance dose for elderly patients or those less than 70 kg body weight is 300 mg, 12-hourly following an initial week of therapy on 200 mg, 12-hourly. The usual maintenance dose for patients of 70 kg body weight or over is 400 mg, 12-hourly following an initial week of therapy on 200 mg or 300 mg, 12-hourly. **Children:** Not recommended for children under seven years of age. The maintenance dose is 9 mg/kg twice daily. Some children with chronic asthma require and tolerate much higher doses (10-16 mg/kg twice daily). Lower dosages (based on usual adult dose) may be required by adolescents. It may be appropriate to administer a larger evening or morning dose in some patients, in order to achieve optimum therapeutic effect when symptoms are quite severe, e.g. at the time of the 'morning dip' in lung function. In patients whose night time or day time symptoms persist despite other therapy and who are not currently receiving theophylline, then the total daily requirement of UNIPHYLLIN CONTINUS tablets (as specified above) may be added to their treatment regimen as either a single evening or morning dose. **Elderly:** The initial dose should be 200 mg, 12-hourly increasing to 300 mg, 12-hourly. **Contra-indications** Should not be given concomitantly with ephedrine in children. **Precautions and warnings** The following increase clearance and it may therefore be necessary to increase dosage to ensure a therapeutic effect: phenytoin, carbamazepine, rifampicin, sulphapyrazone and barbiturates. Smoking and alcohol consumption can also increase clearance of theophylline. The following reduce clearance and a reduced dosage may therefore be necessary to avoid side-effects: allopurinol, cimetidine, ciprofloxacin, erythromycin, thiabendazole, isoprenaline, fluvoxamine, viloxazine hydrochloride and oral contraceptives. Factors such as viral infections, liver disease and heart failure also reduce theophylline clearance. The hypotension resulting from beta₂ agonist therapy

headache and CNS stimulation is significantly reduced when UNIPHYLLIN CONTINUS tablet preparations are given. Furthermore, the side effects can be minimised by dose titration downwards. **Transferability:** It is not possible to ensure bioequivalence between different sustained release theophylline products. Therefore, it should be emphasised that patients, once treated to an effective dose, should not be changed from UNIPHYLLIN CONTINUS tablet preparations to other slow or sustained release xanthine preparations without retitration and clinical assessment. **Legal category** P. **Package quantities and basic NHS price** UNIPHYLLIN CONTINUS tablets 400 mg - 56's: £7.32; 250's: £32.36; 1,000's: £125.29. UNIPHYLLIN CONTINUS tablets 300 mg - 56's: £6.17; 250's: £27.89. UNIPHYLLIN CONTINUS tablets 200 mg - 56's: £4.05. Product licence numbers UNIPHYLLIN CONTINUS tablets 400 mg - PL 0337/0074. UNIPHYLLIN CONTINUS tablets 300 mg - PL 0337/0129. UNIPHYLLIN CONTINUS tablets 200 mg - PL 0337/0057. **Product licence holder** Napp Laboratories Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4GW, UK. Tel: 01223 424444. Member of Napp Pharmaceutical Group. Further information is available from: Napp Laboratories Limited. © The NAPP device, UNIPHYLLIN and CONTINUS are Registered Trade Marks © NAPP Laboratories Limited 1995.

Reference: 1. Kidney J, Dominguez M.

Taylor PM, et al. (In press).

Date of preparation: May 1995.



For over 50 years, theophylline has been regarded as a bronchodilator. New evidence demonstrates that this is only part of the story.

UNIPHYLLIN CONTINUS tablets are now believed to exert an anti-inflammatory action. They therefore present a convenient and acceptable choice for preventive therapy - and add a new dimension to asthma management.

DUAL ACTION

Uniphyllin[®]

CONTINUS[®] TABLETS THEOPHYLLINE BP

Breathing new life into asthma therapy

...opionate)
...cribing Information
...to the full data sheet before

...topically active corticosteroid for
...management of asthma.
...and administration
...inhalation only. Use regularly. Onset
...therapeutic effect usually occurs in
...days. Adults: 100 to 1,000
...micrograms twice daily. Children aged 4
...over: 50 to 100 micrograms twice
...daily. Equivalent disease control usually
...obtained at half the daily dose of other
...currently available inhaled steroids.

...ontra-indications: Hypersensitivity.
...Precautions: Special care is needed in
...quiescent pulmonary tuberculosis or
...unstable asthma. Warn patients to seek
...medical advice if they require a
...bronchodilator use increasingly or if it is
...less effective. Consider additional
...steroids and/or maximum dose of
...inhaled corticosteroid. Treat acute
...exacerbations in the normal course of
...disease. Symptoms: Not for relief of acute
...symptoms. A short-acting inhaled
...bronchodilator is required. Systemic
...effects: Adrenal function and reserve
...usually remain within the normal range.
...Some systemic effects may occur in a
...small proportion of adults after long
...term treatment at high doses. Some
...biochemical changes reported in
...children, but no stunting of growth
...observed. Transfer from oral steroids:
...special care is needed. Monitor adrenal
...function. Do not stop Flixotide abruptly.
...Consider additional corticosteroid
...therapy in situations likely to produce
...stress. Pregnancy and lactation: Experience
...is limited. Balance risks against benefits.
...Side effects: Candidiasis of mouth and
...throat. Hoarseness. Rarely, cutaneous
...hypersensitivity. Paradoxical bronchospasm:
...substitute alternative therapy.

...Presentations and Basic NHS cost
...Flixotide Accuhaler: 60 Inhalations.
...100 micrograms - £8.23. 250 micrograms
...- £12.80. 250 micrograms - £12.80.
...100 micrograms - £40.23. Flixotide
...Diskhaler: 120 actuations. 25 micrograms
...- £6.86. 50 micrograms - £11.43.
...25 micrograms - £22.86.
...50 micrograms - £38.86.

...Flixotide Diskhaler: 14 four-place disks
...with Flixotide Diskhaler. 50 micrograms
...- £8.23. 100 micrograms - £12.80.
...50 micrograms - £24.23.
...100 micrograms - £40.23. Flixotide
...Inhaler: 4 four-place disks. 50 micrograms - £7.66.
...20 micrograms - £12.23.
...50 micrograms - £23.66.
...100 micrograms - £39.66.

...Diskhaler and Inhaler Hospital packs
...also available.
...Product licence numbers: 10949/0001,
...10949/0227, 10949/0228, 10949/0229,
...10949/0001, 10949/0002, 10949/0003,
...10949/0004, 10949/0005, 10949/0006,
...10949/0007, 10949/0008.
...Product licence holder Glaxo
...Pharmaceuticals UK Limited, Stockley
...Park West, Uxbridge UB11 1BT.

...POM

The choice is yours



ALLEN & HANBURYS

Further information is available on request from:
Allen & Hanburys Limited
Uxbridge, Middlesex UB11 1BT
Diskhaler, Diskhaler and Flixotide are trade marks of the Glaxo Group of Companies

June 1995

FLIXOTIDE
fluticasone propionate



Designed for control, with safety in mind.

*Now you can find the information
you really need...*






Evidence-Based Medicine

Editors: B Haynes & D Sackett

With 2 million new papers published each year how can you be sure you read all the papers essential for your daily practice, and how can you be sure of the scientific soundness of what you do read? One answer to this dilemma is practising evidence based medicine, basing clinical decisions on the best available scientific evidence.

To meet this need the BMJ Publishing Group together with the American College of Physicians is launching a new journal - *Evidence-Based Medicine*. This new journal is a development of the ACP Journal Club.

Published bi-monthly *Evidence-Based Medicine*, will survey a wide range of international medical journals (at least 70) to identify the key research papers that are scientifically valid and relevant to practice.



Launching in September 1995.
Evidence-Based Medicine will:

- use scientific criteria to select the abstracts from the most important papers from the world's leading journals
- select only those papers which have a direct message for practice
- provide commentaries on the abstracts which will make clear the importance of the papers
- supply educational material to teach you about evidence based medicine
- cover all medical advances that are really important
- cover internal medicine, and the major specialties, including general surgery, paediatrics, obstetrics & gynaecology, psychiatry, general practice, anaesthesiology and ophthalmology.

ACP

Annual Subscription Rate (Volume One, 7 issues - 1995-96)
BMA Members Rate: £35. Personal Rate: £50. Institutional Rate: £80

BMJ

Publishing Group

Order Form

Evidence Based Medicine ISSN: 1357-5376 Publication: Bi-monthly
1995/96 Subscription Rate: £80 (institutional) £50 (personal); £35 (BMA members)

Please tick

Please enter my subscription start date:

I enclose a cheque for (Payable to British Medical Journal)

BMA membership number

Please send me a sample copy

I wish to pay by credit card

American Express/Visa (Barclaycard)/Mastercard (Delete as appropriate)

Card No.

Expiry date:

Signature:

(Your signature is essential when paying by credit card)

Name:

Address:

.....

..... Present Position

Please tick this box if you do not wish your data to be used for direct marketing purposes

N.B. Subscribers in Italy must add 4% to the quoted sterling price, unless they can provide an IVA registration number. Subscribers in the Irish Republic must add 21% VAT to the quoted sterling price, unless they can provide VAT registration number. Subscribers in Belgium must add 6% TVA/BTW to the quoted sterling price, unless they can provide a TVA/BTW registration number.

Return to: BMJ Publishing Group, Journals Marketing Department, PO Box 299, London WC1H 9TD UK Tel: 0171 383 6270 Fax: 0171 383 6402

**New for
asthma...**

**...it goes the
distance**

**not just
a speed
merchant**

Foradil®

eformoterol fumarate - long acting β_2 -agonist

**Complements inhaled
corticosteroids**

Relieves for 12 hours

**Begins to work in
less than 3 minutes**

Prescribing Information ▼@FORADIL eformoterol fumarate **Presentation** 12 micrograms dry powder inhalation capsules for use with breath activated inhaler device. **Indications** Regular maintenance treatment of bronchospasm in patients with reversible obstructive airways disease. **Dosage** Adults including the elderly: 1-2 capsules twice daily. Not recommended for children. **Contra-indications** Hypersensitivity to eformoterol fumarate or lactose. **Precautions** Steroid treatment should continue unchanged. FORADIL is not for relief of acute symptoms – a short-acting β_2 -agonist is required.

Thyrotoxicosis, severe cardiovascular disorders, dysrhythmia, hypokalaemia, diabetes mellitus. Pregnancy and lactation. Avoid use with β -adrenergic blockers. **Side-effects** *Occasionally:* tremor, palpitations, headache. *Rarely:* muscle cramps, myalgia, tachycardia, agitation, dizziness, insomnia, paradoxical bronchospasm, oropharyngeal irritation. **Legal category** POM. **Packs** Dry powder capsules of 12 micrograms (PL0001/0192) together with an inhaler device, in calendar packs of 56 (basic NHS price £24.00). @ denotes registered trademark.

Full prescribing information is available on request from Geigy Pharmaceuticals, Horsham, West Sussex, RH12 4AB. Telephone (01403) 272827.
Date of preparation February 1995.
© Ciba-Geigy PLC 1995



Taking charge of clinical risk..

CLINICAL RISK MANAGEMENT



BMJ
Publishing Group

Edited by CHARLES VINCENT

Risk management has become a major issue in health care, aimed at reducing the probability of patients being harmed during treatment and minimising the subsequent consequences. This timely book is a unique source of reference for managers and clinicians keen to develop effective risk management, containing:

- Practical advice on implementation, the underlying principles, and recognising potential risks
- Chapters on the clinical applications in various specialties, including anaesthesia, obstetrics, paediatrics, and psychiatry
- Contributions from leaders in the field from the UK and USA
- All the information needed to investigate complaints, deal with claims in the optimum way, and reduce the impact of litigation

The definitive guide to improving the quality of care for your patients

Order your copy now

ISBN 0 7279 0947 9 588 pages January 1996
UK £34.95; Overseas £38.00 (BMA members £32.95; £36.00)

BMJ
Publishing Group

...and other management concerns


Quality and Safety in Anaesthesia

Edited by Jonathan Secker Walker

"It is satisfying to find a text that states what quality in anaesthetic practice is really about."

Today's Anaesthetist

ISBN 0 7279 0828 6
192 pages
UK £16.95;
Overseas £19.00
(BMA members
£15.95; £18.00)




Outcomes into Clinical Practice

Edited by Tony Delamothé

A ground-breaking book on outcomes research, focusing on the opportunities to improve clinical effectiveness and set standards for good practice.


ISBN 0 7279 0888 X
169 pages UK £17.95; Overseas £20.00
(BMA members £16.95; £19.00)



Rationing in Action

Expert advice on the implications of rationing to health providers and their patients.

ISBN 0 7279 0813 8 160 pages
UK £10.95;
Overseas £13.00
(BMA members
£9.95; £12.00)




Management for Doctors

Edited by Jenny Simpson and Richard Smith

"An insightful and inspiring guide for any doctor who wants to know and understand more about NHS management."

Journal of the Royal College of Physicians

ISBN 0 7279 0858 8
200 pages UK £12.95; Overseas £15.00
(BMA members £11.95; £14.00)



ORDER FORM

Available from: BMJ Publishing Group, P.O. Box 295, London WC1H 9TE (Tel: 0171 383 6185/6245), medical booksellers or the BMJ bookshop in BMA House

Please send me

- copy/ies of **Clinical Risk Management**
- copy/ies of **Quality and Safety in Anaesthesia**
- copy/ies of **Outcomes into Clinical Practice**
- copy/ies of **Rationing in Action**
- copy/ies of **Management for Doctors**

BMA Membership No. _____

Name _____

(Print clearly)

Address _____

Postcode _____

Cheque enclosed (made payable to British Medical Journal) £ _____

Debit my American Express/Visa/Mastercard

Card No. _____ Exp _____

Signature _____


Please send me a BMJ Publishing Group Catalogue

How to do it even better!

The highly popular *How To Do It* series is a collection of expert advice on an enormous range of topics that doctors need to know about that are not necessarily covered in formal training.

All three volumes have now been completely updated, with new chapters, and a user friendly format where subjects are grouped into themes. Whether you want to chair a committee, improve your counselling skills with cancer patients, or even survive a formal dinner, your questions will be answered in these entertaining and practical guides.


A must for all doctors, from students through to the retired.



How to Do It Volume 1

- Management ● Employment
- Counselling


ISBN 0 7279 0848 0 272 pages April 1995
UK £12.95; Overseas £15.00
(BMA members £11.95; £14.00)



How to Do It Volume 2

- Examinations ● Academia
- Research and Communication

ISBN 0 7279 0895 2 240 pages April 1995
UK £12.95; Overseas £15.00
(BMA members £11.95; £14.00)



How to Do It Volume 3

- Writing ● Publishing and Publicity
- Something Different

ISBN 0 7279 0896 0 264 pages April 1995
UK £12.95; Overseas £15.00
(BMA members £11.95; £14.00)

Purchase the complete set at a reduced price!

ISBN 0 7279 0906 1 UK £34.95; Overseas £39.00 (BMA members £31.95; £36.00)


BMJ
Publishing
Group

Also available: How to Write a Paper Edited by G M Hall

"Highly recommended as a practical and readable guide to getting published."

Journal of the Institute of Health Education

ISBN 0 7279 0822 7 128 pages 1994 UK £8.95; Overseas £11.00 (BMA members £8.45; £10.50)



Order Form

Available from: **BMJ Publishing Group, P.O. Box 295, London WC1H 9TE, (Tel: 0171 383 6185/6245), medical booksellers or the BMJ bookshop in BMA House**

Please send me _____ copy/ies of HOW TO DO IT VOLUME 1

Address _____

Please send me _____ copy/ies of HOW TO DO IT VOLUME 2

Please send me _____ copy/ies of HOW TO DO IT VOLUME 3

_____ Postcode _____

Please send me _____ COMPLETE SET/S OF HOW TO DO IT

Cheque enclosed (made payable to British Medical Journal) £ _____
Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Please send me _____ copy/ies of HOW TO WRITE A PAPER

Card No. _____ Exp _____

BMA Membership No. _____

Signature _____

Name _____
(Print Clearly)


Please send me a BMJ PUBLISHING GROUP CATALOGUE

PRESCRIBING INFORMATION

Presentations: Pulmicort Respules, (2ml single dose unit ampoules) containing 0.25mg/ml or 0.5mg/ml budesonide in a suspension for nebulisation. **Uses:** Bronchial asthma where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. **Dosage and administration:** Dosage schedules: Administer from suitable nebulisers. Dose delivered to the patient varies depending on the nebulising equipment used (see data sheet). Adjust dosage individually. Initially during periods of severe asthma and while reducing or discontinuing oral glucocorticosteroids the recommended dose in adults (including elderly and children 12 years and older) is usually 1-2mg twice daily. In very severe cases the dosage may be further increased. Children 3 months to 12 years: 0.5-1mg twice daily. The maintenance dose should be the lowest dose which keeps the patient symptom-free. Recommended doses are: Adults (including elderly and children 12 years and older): 0.5-1mg twice

daily. Children (3 months to 12 years): 0.25-0.5mg twice daily. For an increased therapeutic effect increase dose of Pulmicort rather than combine treatment with oral corticosteroids because of the lower risk of systemic effects. **Contra-indications, warnings, etc.:** Contra-indications: Hypersensitivity to any of the constituents. Special warnings and precautions: Care is needed in patients with pulmonary tuberculosis and viral infections in the airways. A short course of oral steroids in addition to Pulmicort may be required in patients with excessive mucus in the bronchi. Transfer of patients dependent on oral steroids to Pulmicort demands special care: see data sheet for further details. The nebuliser chamber should be cleaned and dried after every administration. Pulmicort does not affect the ability to drive and use machines. Pulmicort Respules can be mixed with 0.9% saline and with solutions of terbutaline, salbutamol, sodium cromoglycate or ipratropium bromide. **Side-effects:**

Mild irritation in the throat, coughing and hoarseness and oral candidiasis have been reported. In rare cases inhaled drugs may provoke bronchoconstriction in hyperreactive patients. Facial skin should be washed after use of the face mask as irritation can occur. Coughing can usually be prevented by inhaling a β_2 -agonist (e.g. terbutaline) 5-10 minutes before inhalation of Pulmicort Respules. Avoid in pregnancy. **Pharmaceutical precautions:** Store below 30°C. Use within 3 months of opening the foil envelope. Protect opened ampoule from light. Use within 12 hours of opening. **Legal status:** POM. **Basic NHS price:** Pulmicort Respules 0.25mg/ml (20 single dose units) £32.00. Pulmicort Respules 0.5mg/ml (20 single dose units) £44.64. **Product licence nos.:** Pulmicort Respules 0.25mg/ml PL 0017/0309. Pulmicort Respules 0.5mg/ml PL 0017/0310. **Name and address of product licence holder:** Astra Pharmaceuticals Ltd., Home Park, Kings Langley, Herts WD4 8DH.



Inspired control you can trust

Astra Pharmaceuticals Ltd.,
Home Park,
Kings Langley,
Herts WD4 8DH.



© Registered Trademark
Date of preparation: May 1995
P.Res. 0382

Pulmicort[®]
 **Respules[®]**
BUDESONIDE

Nebulised Steroid Control